Cartilage metabolism in the injured and uninjured knee of the same patient

L Dahlberg, H Roos, T Saxne, D Heinegård, M W Lark, L A Hoermer, L S Lohmander

Abstract

Objective—To examine if unilateral knee injury affects the synovial fluid concentrations of aggrecan fragments, cartilage oligomeric matrix protein (COMP) fragments, stromelysin-1, and tissue inhibitor of metalloproteinases-1 (TIMP-1) in the contralateral uninjured knee.

Methods—Synovial fluids from the injured and uninjured knees were obtained at different times in a group of patients after unilateral knee trauma. Serum samples were obtained on the same occasion. Concentrations of aggrecan fragments were determined by precipitation with Alcian Blue; those of COMP fragments, stromelysin-1, and TIMP-1 were measured by immunoassay. Concentrations were compared with those in a reference group of 10 healthy volunteers.

Results—Immediately after knee injury, concentrations of aggrecan fragments, COMP fragments, stromelysin-1 and TIMP-1 were increased in the synovial fluid of the injured knee. However, concentrations of aggrecan and COMP fragments, and stromelysin-1 increased also in the contralateral uninjured knee immediately after injury, but less than in the injured knee. Subsequently, the concentrations of all markers decreased in the synovial fluid of the injured knee, but remained unchanged in the uninjured knee. The concentration of aggrecan fragments in the injured knee decreased to less than that in the uninjured knee in the chronic phase. Serum concentrations of COMP were much smaller than those in synovial fluid.

Conclusions—The increased concentrations of aggrecan and COMP fragments and stromelysin-1 in the joint fluid of the contralateral, uninjured knee following unilateral knee injury, compared with concentrations in healthy reference knees, suggest changes in joint cartilage metabolism in both knees following unilateral knee injury. The mechanisms for these changes are unclear. The low serum concentration of COMP makes it less likely that there is any significant 'exchange' of molecular markers between the knees. A further consequence of these findings is that the contralateral knee cannot be recommended as the only control joint in studies of matrix metabolism in patients with unilateral knee injury.

Patients and methods

PATIENTS

The study included 54 patients with acute or previous trauma to one knee and no earlier known trauma to the other knee. Patients were examined by arthroscopy and radiography of the injured but not the uninjured knee. Synovial fluids were aspirated from the injured and uninjured knee before the arthroscopy, and on the same occasion a serum sample was obtained. Aspiration of joint fluid was equally successful in both the injured and uninjured knees. Only patients without any radiographic signs of knee OA were included. The patients were assigned to one of three groups with respect to time after the trauma (the time when the symptoms of the injured knee started): the acute group (11 patients with samples obtained up to four
weeks after the knee trauma), the subacute group (samples obtained 4–52 weeks after trauma) or the chronic group (samples obtained more than 52 weeks after trauma) (table 1).

Arthroscopy showed a combination of cruciate ligament, collateral ligament and meniscus injuries in 31 patients. Fifteen patients had isolated meniscus injuries, and eight patients had cartilage lesions without ligament injuries. The different injuries were equally distributed in the three groups. Four of the patients with cruciate ligament injury had undergone ligament reconstruction more than three years before the sampling. Thirty-four patients did not have any arthroscopic cartilage changes. The remaining patients had fibrillations and occasional clefts in the joint cartilage surface in one knee compartment, but normal radiographic findings.

Ten healthy athletes without knee symptoms and with no previous knee injury were used as a reference group1,5 (table 1).

### Table 1
Number of patients (n), time since trauma (Time), and volume (Vol.) of aspirated synovial fluid from the injured and uninjured knee in the four study groups

<table>
<thead>
<tr>
<th>Time (weeks)</th>
<th>1</th>
<th>4</th>
<th>7</th>
<th>23</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>11</td>
<td>14</td>
<td>29</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>Age (yr)*</td>
<td>24</td>
<td>18</td>
<td>22</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Vol. injured (ml)</td>
<td>7.5</td>
<td>0.5</td>
<td>0.6</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Vol. uninjured (ml)</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Age at time of injury</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>10</td>
</tr>
</tbody>
</table>

*Age at time of injury. For definition of groups see Patients and methods.

Table 2  Synovial fluid aggrecan (AGN) fragments, COMP, stromelysin-1 (SLN) and TIMP-1 concentrations in synovial fluid of the injured and uninjured knee in the study groups, and serum COMP concentrations

<table>
<thead>
<tr>
<th>Synovial fluid</th>
<th>Injured</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AGN (μg/ml)</td>
<td>Acute</td>
<td>Subacute</td>
<td>Chronic</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>14</td>
<td>29</td>
<td>11</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>98</td>
<td>50</td>
<td>43</td>
<td>58</td>
<td>42</td>
<td>14</td>
</tr>
<tr>
<td>133</td>
<td>103</td>
<td>54</td>
<td>76</td>
<td>76</td>
<td>52</td>
</tr>
<tr>
<td>387</td>
<td>164</td>
<td>70</td>
<td>86</td>
<td>98</td>
<td>67</td>
</tr>
<tr>
<td>COMP (μg/ml)</td>
<td>Acute</td>
<td>Subacute</td>
<td>Chronic</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>13</td>
<td>27</td>
<td>11</td>
<td>13</td>
<td>27</td>
</tr>
<tr>
<td>115</td>
<td>70</td>
<td>62</td>
<td>93</td>
<td>77</td>
<td>16</td>
</tr>
<tr>
<td>130</td>
<td>102</td>
<td>89</td>
<td>124</td>
<td>113</td>
<td>43</td>
</tr>
<tr>
<td>172</td>
<td>145</td>
<td>115</td>
<td>136</td>
<td>138</td>
<td>73</td>
</tr>
<tr>
<td>SLN (nmol/l)</td>
<td>Acute</td>
<td>Subacute</td>
<td>Chronic</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>24</td>
<td>7</td>
<td>24</td>
<td>10</td>
</tr>
<tr>
<td>50</td>
<td>0.1</td>
<td>2.6</td>
<td>4.1</td>
<td>0.2</td>
<td>1.7</td>
</tr>
<tr>
<td>191</td>
<td>2.9</td>
<td>8</td>
<td>6.7</td>
<td>3.5</td>
<td>2.6</td>
</tr>
<tr>
<td>474</td>
<td>95</td>
<td>14</td>
<td>61</td>
<td>8</td>
<td>4.8</td>
</tr>
<tr>
<td>TIMP-1 (nmol/l)</td>
<td>Acute</td>
<td>Subacute</td>
<td>Chronic</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>8</td>
<td>24</td>
<td>7</td>
<td>24</td>
<td>10</td>
</tr>
<tr>
<td>42</td>
<td>5.9</td>
<td>5.9</td>
<td>6.5</td>
<td>5.9</td>
<td>0.5</td>
</tr>
<tr>
<td>69</td>
<td>7.5</td>
<td>7.5</td>
<td>6.7</td>
<td>6.7</td>
<td>4.8</td>
</tr>
<tr>
<td>155</td>
<td>18</td>
<td>9.2</td>
<td>8.3</td>
<td>5.7</td>
<td>7.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Serum</th>
<th>Injured</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>COMP (μg/ml)</td>
<td>Acute</td>
<td>Subacute</td>
<td>Chronic</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>14</td>
<td>29</td>
<td>11</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>5-1</td>
<td>7.2</td>
<td>6.5</td>
<td>5.8</td>
<td>6.8</td>
<td>5.6</td>
</tr>
<tr>
<td>7-3</td>
<td>7.9</td>
<td>7.5</td>
<td>6.7</td>
<td>7.5</td>
<td>4.7</td>
</tr>
<tr>
<td>8-4</td>
<td>9.5</td>
<td>9.2</td>
<td>8.3</td>
<td>5.7</td>
<td>7.3</td>
</tr>
</tbody>
</table>

n = Number of patients; for definition of groups, see Patients and methods.

The total number of samples analysed with each method differs because of lack of fluid. Concentrations for each group are given as the 25th percentile value at the top, median value (bold) in the middle, and 75th percentile value at the bottom.

### SAMPLE PREPARATION

Synovial fluid was aspirated with a 1·2 mm needle and a lateral parapatellar approach. The joint fluids were aspirated to dryness and the volumes recorded. The serum and joint fluid samples were centrifuged and then stored at −70°C until analysed.

### MARKER ASSAYS

Aggrecan fragment concentrations were determined by precipitation of chondroitin- and keratan sulphate-containing proteoglycan fragments with Alcian Blue.21 Stromelysin-1 and TIMP-1 concentrations were measured by sandwich immunoassay, using monoclonal and polyclonal antibodies.2 22 23 The assay for stromelysin-1 detects the proform of the enzyme, the large molecular active form and the enzyme complexed to TIMP-1, but not small molecular forms or enzyme complexed to α-2-macroglobulin. The large majority of the enzyme is in the proform.23 The assay for TIMP-1 detects free TIMP-1 but not the inhibitor complexed with metalloproteinases.

COMP concentrations in synovial fluid and serum were determined by a competition immunnoassay.24 Antibodies were raised in a rabbit immunised with purified bovine COMP. Microtitre plates were coated with human COMP and a set of standards using different concentrations of human COMP was included in each plate.

### STATISTICAL ANALYSIS

Wilcoxon’s matched pairs signed ranks test was used to examine differences between injured and uninjured knees. Mann-Whitney rank sum test for two independent samples was used to calculate differences between the reference group and the injured and uninjured knees. For correlation analysis the Spearman rank correlation method was used. p < 0.05 was considered significant. All differences and correlations discussed as such are statistically significant at this level or better.

### Results

Marker concentrations in the ipsi- and contra-lateral knees are presented individually, and as median concentration values. Because of lack of fluid, the number of analyses differs between markers. Median concentrations of each marker, however, were calculated using only paired samples (table 2).

There was no difference regarding sex and age distribution between the three study groups, or between these groups and the reference group (table 1). The specific type of knee injury, the degree of arthroscopic cartilage damage, or cruciate ligament reconstruction, did not significantly influence median marker concentrations in these small groups of patients. None of the patients was treated with intra-articular glucocorticoids or was receiving chronic treatment with non-steroidal anti-inflammatory drugs.
Cartilage metabolism in the injured and uninjured knee of the same patient

**INJURED KNEES COMPARED WITH REFERENCE KNEES**

In the acute phase in the injured knee, the concentrations of all markers, aggrecan fragments, COMP fragments, and stromelysin-1 and TIMP-1 were greater than in the reference group (figs 1–3, table 2). With increased time after injury, the concentrations of markers in the injured knee decreased, although COMP, stromelysin-1 and TIMP-1 concentrations were still increased compared with reference values in the chronic phase (figs 1–3, table 2).

**UNINJURED KNEES COMPARED WITH REFERENCE KNEES**

In the acute phase in the uninjured knee, the joint fluid concentrations of aggrecan fragments, COMP fragments, and stromelysin-1 were higher than in the reference group. The TIMP-1 concentration did not differ from the reference values (figs 1–3, table 2). Unlike the concentrations of markers in the injured knee, there was no significant change in joint fluid marker concentrations in the uninjured knee over time. Thus concentrations of aggrecan fragments, COMP fragments, and stromelysin-1 were increased compared with reference values in the chronic phase also (figs 1–3, table 2).

The ratios of aggrecan to COMP were similar in the acute, subacute and chronic phases in both the injured and uninjured knee, and did not differ from the reference ratio (data not shown). Furthermore, in the chronic phase, there was a correlation between the concentrations of aggrecan and COMP fragments in both the injured and uninjured knees. There was no correlation between stromelysin-1 and aggrecan fragment concentrations (data not shown). This may be because the assay used also detects the proform of the enzyme, and most of the enzyme in joint fluid is present in the proform.23

**COMPARISON BETWEEN INJURED AND UNINJURED KNEES**

In the acute phase, the injured knee had greater concentrations of aggrecan fragments, stromelysin-1, and TIMP-1 compared with the uninjured joint. However, concentrations of COMP did not differ between the knees (figs 1–3, table 2).

In the subacute phase, the concentrations of aggrecan and COMP fragments and stromelysin-1 were similar in both knees, but TIMP-1 concentrations were greater in the injured knee (figs 1–3, table 2).
In the chronic phase, the injured knee had a smaller median concentration of aggrecan fragments, COMP concentrations did not differ, and stromelysin-1 and TIMP-1 concentrations were greater in the injured knee (figs 1–3, table 2).

In the chronic phase, there was a correlation between the injured and uninjured knees with respect to both aggrecan fragment and COMP concentrations (fig 4).

Serum COMP concentrations were approximately 10% of the joint fluid COMP concentrations (table 2). There was no difference in the serum COMP concentrations between the acute, subacute, and chronic phases. Serum and joint fluid COMP concentrations did not correlate.

When the data were expressed as total content of synovial fluid markers (calculated as the product between the concentration of the marker and the aspirated synovial fluid volume) rather than as concentration values, similar results were obtained. However, in common with findings in previous studies, there was a greater variability in these values, as a result of uncertainties in estimates of total joint fluid volume (data not shown).² ²⁵

Discussion

The temporal patterns of marker concentrations in the synovial fluid in the injured knee of the patients with unilateral knee injury in the present study is in agreement with those previously reported for post-traumatic patients.¹ ³ ⁴ ⁵ However, in the present study we also examined marker concentrations in the contralateral, uninjured knee in the same patients. We found increased concentrations of aggrecan and COMP fragments, and of stromelysin-1 in the synovial fluid of the uninjured knee both early and late after the trauma. These findings may be consistent with an altered matrix metabolism not only in the injured, but also in the uninjured knee. This would corroborate previous investigations in post-traumatic animals in which studies of radioisotope incorporation in the joint cartilage and aggrecan concentration in synovial joint fluids have indicated an altered cartilage metabolism in the unoperated contralateral knee joint.¹⁷ ¹⁹

Recently, two studies have compared injured and uninjured human knees with respect to the synovial fluid content of several different aggrecan epitopes.²⁶ ²⁷ Results were variable, but indicated a greater content of chondroitin sulphate epitopes and sulphated glycosaminoglycans in the injured compared with the uninjured knee. To decrease the influence of interindividual variations, we included only patients in whom it was possible to obtain paired, undiluted samples. Further, the patients were assigned to an acute, subacute, or chronic group because of the marked influence of time after injury on marker concentrations shown by our previous studies.¹ ³ ⁴ ⁵ Patients with radiographic OA were excluded from our study, since severe cartilage changes were shown to influence concentrations of markers in synovial fluid.²⁸

As a final control, we compared the synovial fluid marker concentrations in the injured patients with those in a reference group having healthy knees.

Several factors may influence cartilage matrix metabolism in the uninjured knee of patients with a unilateral knee injury. Gait and biomechanical analyses have shown that patients with unilateral cruciate ligament deficiency prevent the anterior translation and internal-external rotation of the knee by the use of a more flexed hip position in strenuous situations.¹³ Such patients also use antalgic manoeuvres frequently,¹⁴ and have a bilateral leg impairment in performance tests.¹⁵ Animal studies have shown that joint loading induces alterations in the articular cartilage,²⁹ ³⁰ and in a study of aggrecan fragments in joint fluid before and after physical exercise in healthy athletes, the concentration of this marker was moderately increased after exercise.³¹

The low serum concentration of COMP fragments makes it unlikely that matrix fragments in one joint originate from another joint. However, it is possible that cytokines and degraded matrix products released from a diseased joint and transported to other healthy joints by the circulation can be involved in the early initiation of pathological processes in uninjured joints.³² This concept is supported by a report that, in mice, intraperitoneal injection of purified cartilage proteoglycans digested with chondroitinase resulted in synovial inflammation and erosion of the articular tissues.³²

The results of this study suggest an altered cartilage matrix metabolism not only in the injured, but also in the uninjured knee in patients with unilateral knee injury. The pathophysiological significance and the mechanisms responsible for this finding are not understood. However, the contralateral knee cannot be recommended as the only control joint in studies of matrix metabolism in patients with unilateral knee injury.

The helpful cooperation of the staff of the Department of Orthopedics, Lund University Hospital is greatly appreciated, as is the expert technical assistance of Chris Ebner, Elisaveta Triguteiro, and Mariette Halbeck. Supported by the Swedish Medical Research Council, the Medical Faculty of Lund University, The Zoega, Kock, Axon Johnson and Procordia, and Osteoarthritis, the King Gustaf V 80-Year Birthday Fund, Svenska Sällskapet för Medicinsk Forskning, Stiftelsen för Vanföra i Skåne, Riksstiftelsen mot Reumatism, and Mercy Research Laboratories.
Cartilage metabolism in the injured and uninjured knee of the same patient


Cartilage metabolism in the injured and uninjured knee of the same patient.

L Dahlberg, H Roos, T Saxne, D Heinegård, M W Lark, L A Hoerrner and L S Lohmander

Ann Rheum Dis 1994 53: 823-827
doi: 10.1136/ard.53.12.823

Updated information and services can be found at:
http://ard.bmj.com/content/53/12/823

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/